Share this article and save a life!
Health AI just had its biggest funding month of 2026.
And the money is not going where most people think.
Let me break down what happened in the last few weeks and why it matters for everyone in healthcare.
🚀 The deals that stood out:
Abridge, the ambient clinical documentation company, closed a $250M Series D, bringing its total funding to over $450M. They are embedded in Epic workflows at dozens of health systems and processing millions of clinical conversations per year.
Waystar, the revenue cycle AI platform, continues expanding after its 2024 IPO with new AI modules focused on prior authorization automation. Health systems report 30 to 40 percent reductions in denial rates using AI-assisted coding.
Hippocratic AI, which builds AI agents for patient communication and care navigation, raised a $141M Series B at a $1.64B valuation. They are targeting FQHCs and safety-net providers specifically, where staff-to-patient ratios are the worst.
Daybreak Health, focused on youth behavioral health, secured $40M to expand mental health access in school-based and FQHC settings.
📌 Here is what the pattern tells us:
Investors are no longer funding AI for the sake of AI. They are funding AI that sits directly inside clinical workflows, solves reimbursement problems, or addresses the staffing crisis that every provider organization is drowning in.
Ambient documentation alone is projected to save physicians 2 hours per day on average. At current physician burnout rates, that is not a nice-to-have. It is an operational survival tool.
Revenue cycle AI is getting serious attention because denials are up 67 percent since 2020 according to AHA data. Every percentage point of denial rate reduction translates to millions in recovered revenue for mid-size health systems.
And the safety-net focus is new. Companies like Hippocratic AI are explicitly building for FQHCs because the unmet need is massive and the reimbursement models are finally maturing enough to support it.
The honest question nobody is asking:
Are health systems building internal AI capacity fast enough to actually absorb and govern all of this technology, or are we funding tools that will sit unused because the change management infrastructure does not exist?
Every major health AI company needs a clinical champion, an IT integration pathway, a compliance review, and a reimbursement strategy. Most hospitals struggle to execute even two of those at once.
Funding is not adoption. Adoption is not outcomes.
The smartest leaders I talk to are not asking which AI tools to buy. They are asking how to build the internal muscle to evaluate, implement, and measure AI at scale.
That is the real competitive advantage in 2026.
♻️ Repost if your organization is still trying to figure out which AI tools are actually worth implementing.
👉 Follow me for daily healthcare updates and get the deeper analysis in my free newsletter → https://oatmealhealthjonathangovette.substack.com/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
